Idorsia Pharmaceuticals Ltd: Swissmedic approves QUVIVIQ (daridorexant) - a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning
QUVIVIQ is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioningQUVIVIQ, Switzerland's first